申请人:Cadent Therapeutics, Inc.
公开号:US10626122B2
公开(公告)日:2020-04-21
Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated modulate the NMDA receptor.
本文部分公开了杂芳香族化合物和用于治疗神经精神疾病(如精神分裂症和重度抑郁症)的方法。提供了药物组合物和制造杂芳香族化合物的方法。这些化合物可以调节 NMDA 受体。